Analyst Viewpoint
Rise in prevalence of infectious diseases is one of the key factors driving the demand for various types of vaccines across the globe. Increase in vaccination and immunization programs conducted by public healthcare organizations and governments is also fueling market progress. Furthermore, surge in advancements in immunology is augmenting the vaccines industry growth.
Children and the elderly population are more prone to infectious diseases. Thus, vaccination and immunization plays a crucial role in their well-being. Manufacturers are increasingly carrying out advancements such as genetic engineering and lab automation to strengthen their vaccines market share. They are also investing significantly in research and development activities to introduce new vaccines for major infectious diseases.
Vaccine is a biological preparation that provides active acquired immunity to a particular malignant or infectious disease. It contains an agent that resembles a disease-causing microorganism and is made from killed or weakened forms of the microbe, its toxins, or one of its surface proteins.
Vaccination is a safe, effective, and simple way of providing protection against harmful diseases. It uses the body’s natural defenses to build resistance to specific infections and makes the immune system stronger.
There are several types of vaccines such as live-attenuated vaccines, inactivated vaccines, messenger RNA (mRNA) vaccines, toxoid vaccines, viral vector vaccines, subunit, recombinant, polysaccharide, and conjugate vaccines.
Vaccines contain synthetically manufactured, weakened, or killed versions of the disease-causing germ or parts of the germ called antigens.
Infectious diseases such as tuberculosis, dengue, influenza, HIV, and malaria require proper cure at their initial stage to avoid severe health consequences. Rise in prevalence of these diseases among the global population is bolstering market development.
Manufacturers of vaccines are focusing on expanding their production capacity to meet the increasing consumer demand. According to the European Centre for Disease Prevention and Control, approximately 4.5 million dengue cases were reported globally, while 4000 deaths were confirmed until the beginning of November 2023.
Increase in prevalence of infectious diseases among children is fueling the demand for preventive vaccines. Rise in awareness among people about the benefits of vaccination is expected to drive market trajectory in the next few years.
As per a report by the World Health Organization 2023, the number of zero-dose children improved from 18.1 million in 2021 to 14.3 million in 2022. Also, 84% of the children were vaccinated with a third dose of vaccine protecting against Diphtheria, Tetanus, and Pertussis (DTP3).
Therapeutic vaccines are used to treat various illnesses such as infectious diseases, allergies, physical disorders, and cancer. Increase in advancements in immunology is anticipated to boost the vaccines market size in the next few years.
Companies in the vaccines sector are focusing on therapeutic vaccine development for diseases such as dyslipidemia, inflammatory diseases, cancer, Alzheimer’s disease, and hypertension. For instance, in January 2022, Pfizer Inc. and BioNTech SE commenced a clinical evaluation to identify tolerability, safety, and immunogenicity of the Omicron-based vaccine in adults.
Growth in investment in research and development activities is also likely to augment the availability of vaccines across the globe. Healthcare organizations are carrying out mass vaccination programs to increase the vaccination rate across the globe.
Lab automation and adoption of mRNA vaccines are some of the key vaccines industry trends adopted by the leading companies. mRNA vaccines can be developed at a faster rate using the pathogen’s genetic code. Such advancements are expected to fuel market dynamics.
As per the latest vaccines market forecast, North America accounted for dominant share in 2022. Rapid development in the healthcare sector in the U.S. is augmenting market statistics in the region.
Ongoing medical research activities by manufacturers are leading to an increase in product development rate in North America. Rise in investment from government and non-government organizations in research and development of vaccines is another key factor that is likely to boost the region’s vaccines industry size in the upcoming years.
Asia Pacific is anticipated to record significant market expansion in the near future due to the growth in patient population. Increase in government spending on immunization programs such as the Universal Immunization Program is fueling the sector in the region. The Universal Immunization Program aims to prevent diseases such as smallpox, polio, and measles.
According to the vaccines market research report, key players are adopting various strategies such as partnership agreements and new product launches to expand their footprint and maintain their leading position.
AstraZeneca, GlaxoSmithKline PLC, Sanofi Pasteur SA, Pfizer, Inc., Panacea Biotec, Merck & Co., Inc., Janssen Pharmaceutical Company, Serum Institute of India Ltd, Emergent BioSolutions Inc., CSL, Bavarian Nordic, IBSS BIOMED S.A., Novavax AB, and Mitsubishi Tanabe Pharma Corporation are some of the prominent players operating in the global landscape.
Each of these companies has been profiled in the vaccines industry forecast report based on parameters such as business strategies, company overview, business segments, financial overview, recent developments, and product portfolio
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 119.1 Bn |
| Market Forecast (Value) in 2031 | US$ 99.3 Bn |
| Growth Rate (CAGR) | 4.2% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2022 |
| Quantitative Tons | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 119.1 Bn in 2022
It is anticipated to grow at a CAGR of 4.2% from 2023 to 2031
Rise in prevalence of infectious diseases and increase in advancements in immunology
North America was the most lucrative region in 2022
AstraZeneca, GlaxoSmithKline PLC, Sanofi Pasteur SA, Pfizer, Inc., Panacea Biotec, Merck & Co., Inc., Janssen Pharmaceutical Company, Serum Institute of India Ltd, Emergent BioSolutions Inc., CSL, Bavarian Nordic, IBSS BIOMED S.A., Novavax AB, and Mitsubishi Tanabe Pharma Corporation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Vaccines Market
4. Market Overview
4.1. Introduction
4.2. Definition
4.3. Industry Evolution / Developments
4.4. Overview
4.5. Market Dynamics
4.5.1. Drivers
4.5.2. Restraints
4.5.3. Opportunities
4.6. Global Vaccines Market Analysis and Forecast, 2017-2031
4.6.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario
5.2. Key Distribution Strategies
5.3. Pricing Analysis
5.4. Patents on Vaccines
5.5. Technological Advancements in Vaccines
5.6. Vaccine Type - Overview
5.7. COVID-19 Pandemic Impact on Industry
6. Global Vaccines Market Analysis and Forecast, by Vaccine
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Vaccine, 2017-2031
6.3.1. Inactivated
6.3.2. Live Attenuated
6.3.3. Toxoid
6.3.4. Conjugate
6.3.5. Others
6.4. Market Attractiveness Analysis, by Vaccine
7. Global Vaccines Market Analysis and Forecast, by Valance
7.1. Introduction & Definition
7.2. Developments
7.3. Market Value Forecast, by Valance, 2017-2031
7.3.1. Monovalent
7.3.2. Multivalent
7.4. Market Attractiveness Analysis, by Valance
8. Global Vaccines Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017-2031
8.3.1. Oral
8.3.2. Injectable
8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Vaccines Market Analysis and Forecast, by Indication
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Indication, 2017-2031
9.3.1. Influenza
9.3.2. Hepatitis
9.3.3. Polio
9.3.4. Meningococcal Disease
9.3.5. Pneumococcal Disease
9.3.6. DTP
9.3.7. Rotavirus
9.3.8. MMR
9.3.9. Human Papilloma Virus
9.3.10. Others
9.4. Market Attractiveness Analysis, by Indication
10. Global Vaccines Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2017-2031
10.3.1. Institutional Sales
10.3.2. Hospital Pharmacies
10.3.3. Retail Pharmacies
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Vaccines Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017-2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Vaccines Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Vaccine, 2017-2031
12.3.1. Inactivated
12.3.2. Live Attenuated
12.3.3. Toxoid
12.3.4. Conjugate
12.3.5. Others
12.4. Market Value Forecast, by Valance, 2017-2031
12.4.1. Monovalent
12.4.2. Multivalent
12.5. Market Value Forecast, by Route of Administration, 2017-2031
12.5.1. Oral
12.5.2. Injectable
12.5.3. Others
12.6. Market Value Forecast, by Indication, 2017-2031
12.6.1. Influenza
12.6.2. Hepatitis
12.6.3. Polio
12.6.4. Meningococcal Disease
12.6.5. Pneumococcal Disease
12.6.6. DTP
12.6.7. Rotavirus
12.6.8. MMR
12.6.9. Human Papilloma Virus
12.6.10. Others
12.7. Market Value Forecast, by Distribution Channel, 2017-2031
12.7.1. Institutional Sales
12.7.2. Hospital Pharmacies
12.7.3. Retail Pharmacies
12.8. Market Value Forecast, by Country/sub-region, 2017-2031
12.8.1. U.S.
12.8.2. Canada
12.9. Market Attractiveness Analysis
12.9.1. By Vaccine
12.9.2. By Valance
12.9.3. By Route of Administration
12.9.4. By Indication
12.9.5. By Distribution Channel
12.9.6. By Country
13. Europe Vaccines Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Vaccine, 2017-2031
13.3.1. Inactivated
13.3.2. Live Attenuated
13.3.3. Toxoid
13.3.4. Conjugate
13.3.5. Others
13.4. Market Value Forecast, by Valance, 2017-2031
13.4.1. Monovalent
13.4.2. Multivalent
13.5. Market Value Forecast, by Route of Administration, 2017-2031
13.5.1. Oral
13.5.2. Injectable
13.5.3. Others
13.6. Market Value Forecast, by Indication, 2017-2031
13.6.1. Influenza
13.6.2. Hepatitis
13.6.3. Polio
13.6.4. Meningococcal Disease
13.6.5. Pneumococcal Disease
13.6.6. DTP
13.6.7. Rotavirus
13.6.8. MMR
13.6.9. Human Papilloma Virus
13.6.10. Others
13.7. Market Value Forecast, by Distribution Channel, 2017-2031
13.7.1. Institutional Sales
13.7.2. Hospital Pharmacies
13.7.3. Retail Pharmacies
13.8. Market Value Forecast, by Country/sub-region, 2017-2031
13.8.1. Germany
13.8.2. U.K.
13.8.3. France
13.8.4. Italy
13.8.5. Spain
13.8.6. Rest of Europe
13.9. Market Attractiveness Analysis
13.9.1. By Vaccine
13.9.2. By Valance
13.9.3. By Route of Administration
13.9.4. By Indication
13.9.5. By Distribution Channel
13.9.6. By Country/Sub-region
14. Asia Pacific Vaccines Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Vaccine, 2017-2031
14.3.1. Inactivated
14.3.2. Live Attenuated
14.3.3. Toxoid
14.3.4. Conjugate
14.3.5. Others
14.4. Market Value Forecast, by Valance, 2017-2031
14.4.1. Monovalent
14.4.2. Multivalent
14.5. Market Value Forecast, by Route of Administration, 2017-2031
14.5.1. Oral
14.5.2. Injectable
14.5.3. Others
14.6. Market Value Forecast, by Indication, 2017-2031
14.6.1. Influenza
14.6.2. Hepatitis
14.6.3. Polio
14.6.4. Meningococcal Disease
14.6.5. Pneumococcal Disease
14.6.6. DTP
14.6.7. Rotavirus
14.6.8. MMR
14.6.9. Human Papilloma Virus
14.6.10. Others
14.7. Market Value Forecast, by Distribution Channel, 2017-2031
14.7.1. Institutional Sales
14.7.2. Hospital Pharmacies
14.7.3. Retail Pharmacies
14.8. Market Value Forecast, by Country/sub-region, 2017-2031
14.8.1. China
14.8.2. India
14.8.3. Japan
14.8.4. Australia & New Zealand
14.8.5. Rest of Asia Pacific
14.9. Market Attractiveness Analysis
14.9.1. By Vaccine
14.9.2. By Valance
14.9.3. By Route of Administration
14.9.4. By Indication
14.9.5. By Distribution Channel
14.9.6. By Country/Sub-region
15. Latin America Vaccines Market Analysis and Forecast
15.1. Introduction
15.2. Key Findings
15.3. Market Value Forecast, by Vaccine, 2017-2031
15.3.1. Inactivated
15.3.2. Live Attenuated
15.3.3. Toxoid
15.3.4. Conjugate
15.3.5. Others
15.3.6. Others
15.4. Market Value Forecast, by Valance, 2017-2031
15.4.1. Monovalent
15.4.2. Multivalent
15.5. Market Value Forecast, by Route of Administration, 2017-2031
15.5.1. Oral
15.5.2. Injectable
15.5.3. Others
15.6. Market Value Forecast, by Indication, 2017-2031
15.6.1. Influenza
15.6.2. Hepatitis
15.6.3. Polio
15.6.4. Meningococcal Disease
15.6.5. Pneumococcal Disease
15.6.6. DTP
15.6.7. Rotavirus
15.6.8. MMR
15.6.9. Human Papilloma Virus
15.6.10. Others
15.7. Market Value Forecast, by Distribution Channel, 2017-2031
15.7.1. Institutional Sales
15.7.2. Hospital Pharmacies
15.7.3. Retail Pharmacies
15.8. Market Value Forecast, by Country/sub-region, 2017-2031
15.8.1. Brazil
15.8.2. Mexico
15.8.3. Rest of Latin America
15.9. Market Attractiveness Analysis
15.9.1. By Vaccine
15.9.2. By Valance
15.9.3. By Route of Administration
15.9.4. By Indication
15.9.5. By Distribution Channel
15.9.6. By Country/Sub-region
16. Middle East & Africa Vaccines Market Analysis and Forecast
16.1. Introduction
16.2. Key Findings
16.3. Market Value Forecast, by Vaccine, 2017-2031
16.3.1. Inactivated
16.3.2. Live Attenuated
16.3.3. Toxoid
16.3.4. Conjugate
16.3.5. Others
16.4. Market Value Forecast, by Valance, 2017-2031
16.4.1. Monovalent
16.4.2. Multivalent
16.5. Market Value Forecast, by Route of Administration, 2017-2031
16.5.1. Oral
16.5.2. Injectable
16.5.3. Others
16.6. Market Value Forecast, by Indication, 2017-2031
16.6.1. Influenza
16.6.2. Hepatitis
16.6.3. Polio
16.6.4. Meningococcal Disease
16.6.5. Pneumococcal Disease
16.6.6. DTP
16.6.7. Rotavirus
16.6.8. MMR
16.6.9. Human Papilloma Virus
16.6.10. Others
16.7. Market Value Forecast, by Distribution Channel, 2017-2031
16.7.1. Institutional Sales
16.7.2. Hospital Pharmacies
16.7.3. Retail Pharmacies
16.8. Market Value Forecast, by Country/sub-region, 2017-2031
16.8.1. GCC Countries
16.8.2. South Africa
16.8.3. Rest of Middle East & Africa
16.9. Market Attractiveness Analysis
16.9.1. By Vaccine
16.9.2. By Valance
16.9.3. By Route of Administration
16.9.4. By Indication
16.9.5. By Distribution Channel
16.9.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. AstraZeneca
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. GlaxoSmithKline PLC
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Sanofi Pasteur SA
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Pfizer Inc.
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Panacea Biotec
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Merck & Co., Inc.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Janssen Pharmaceutical Company
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Serus Institute of India Ltd
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Emergent BioSolutions Inc.
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. CSL
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview
17.3.11. Bavarian Nordic
17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.11.2. Product Portfolio
17.3.11.3. Financial Overview
17.3.11.4. SWOT Analysis
17.3.11.5. Strategic Overview
17.3.12. IBSS BIOMED S.A.
17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.12.2. Product Portfolio
17.3.12.3. Financial Overview
17.3.12.4. SWOT Analysis
17.3.12.5. Strategic Overview
17.3.13. Novavax AB
17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.13.2. Product Portfolio
17.3.13.3. Financial Overview
17.3.13.4. SWOT Analysis
17.3.13.5. Strategic Overview
17.3.14. Mitsubishi Tanabe Pharma Corporation
17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.14.2. Product Portfolio
17.3.14.3. Financial Overview
17.3.14.4. SWOT Analysis
17.3.14.5. Strategic Overview
List of Tables
Table 01. Global Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
Table 02. Global Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
Table 03. Global Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 04. Global Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 05. Global Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 06. Global Vaccines Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 07. North America Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
Table 08. North America Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
Table 09. North America Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 10. North America Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 11. North America Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 12. Europe Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 13. Europe Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
Table 14. Europe Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
Table 15. Europe Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 16. Europe Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 17. Europe Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 18. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 19. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
Table 20. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
Table 21. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 22. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 23. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 24. Latin America Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 25. Latin America Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
Table 26. Latin America Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
Table 27. Latin America Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 28. Latin America Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 29. Latin America Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 30. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 31. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
Table 32. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
Table 33. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 34. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 35. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01. Global Vaccines Market Value (US$ Mn) Forecast, 2017-2031
Figure 02. Vaccines Market Value Share, by Vaccine, 2022
Figure 03. Vaccines Market Value Share, by Valance, 2022
Figure 04. Vaccines Market Value Share, by Route of Administration, 2022
Figure 05. Vaccines Market Value Share, by Indication, 2022
Figure 06. Vaccines Market Value Share, by Distribution Channel, 2022
Figure 07. Global Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
Figure 08. Global Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
Figure 09. Global Vaccines Market Value Share Analysis, by Valance 2022 and 2031
Figure 10. Global Vaccines Market Attractiveness Analysis, Valance, 2023-2031
Figure 11. Global Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 12. Global Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
Figure 13. Global Vaccines Market Value Share Analysis, by Indication 2022 and 2031
Figure 14. Global Vaccines Market Attractiveness Analysis, Indication, 2023-2031
Figure 15. Global Vaccines Market Value Share Analysis, by Distribution Channel 2022 and 2031
Figure 16. Global Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
Figure 17. Global Vaccines Market Value Share Analysis, by Region, 2022 and 2031
Figure 18. Global Vaccines Market Attractiveness Analysis, by Region, 2023-2031
Figure 19. North America Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 20. North America Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
Figure 21. North America Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
Figure 22. North America Vaccines Market Value Share Analysis, by Valance 2022 and 2031
Figure 23. North America Vaccines Market Attractiveness Analysis, Valance, 2023-2031
Figure 24. North America Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 25. North America Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
Figure 26. North America Vaccines Market Value Share Analysis, by Indication 2022 and 2031
Figure 27. North America Vaccines Market Attractiveness Analysis, Indication, 2023-2031
Figure 28. North America Vaccines Market Value Share Analysis, by Distribution Channel 2022 and 2031
Figure 29. North America Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
Figure 30. Europe Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 31. Europe Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 32. Europe Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 33. Europe Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
Figure 34. Europe Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
Figure 35. Europe Vaccines Market Value Share Analysis, by Valance, 2022 and 2031
Figure 36. Europe Vaccines Market Attractiveness Analysis, Valance, 2023-2031
Figure 37. Europe Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 38. Europe Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
Figure 39. Europe Vaccines Market Value Share Analysis, by Indication 2022 and 2031
Figure 40. Europe Vaccines Market Attractiveness Analysis, Indication, 2023-2031
Figure 41. Europe Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 42. Europe Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
Figure 43. Asia Pacific Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 44. Asia Pacific Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 45. Asia Pacific Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 46. Asia Pacific Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
Figure 47. Asia Pacific Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
Figure 48. Asia Pacific Vaccines Market Value Share Analysis, by Valance, 2022 and 2031
Figure 49. Asia Pacific Vaccines Market Attractiveness Analysis, Valance, 2023-2031
Figure 50. Asia Pacific Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 51. Asia Pacific Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
Figure 52. Asia Pacific Vaccines Market Value Share Analysis, by Indication 2022 and 2031
Figure 53. Asia Pacific Vaccines Market Attractiveness Analysis, Indication, 2023-2031
Figure 54. Asia Pacific Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 55. Asia Pacific Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
Figure 56. Latin America Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 57. Latin America Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 58. Latin America Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 59. Latin America Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
Figure 60. Latin America Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
Figure 61. Latin America Vaccines Market Value Share Analysis, by Valance, 2022 and 2031
Figure 62. Latin America Vaccines Market Attractiveness Analysis, Valance, 2023-2031
Figure 63. Latin America Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 64. Latin America Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
Figure 65. Latin America Vaccines Market Value Share Analysis, by Indication 2022 and 2031
Figure 66. Latin America Vaccines Market Attractiveness Analysis, Indication, 2023-2031
Figure 67. Latin America Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 68. Latin America Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
Figure 69. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 70. Middle East & Africa Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 71. Middle East & Africa Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 72. Middle East & Africa Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
Figure 73. Middle East & Africa Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
Figure 74. Middle East & Africa Vaccines Market Value Share Analysis, by Valance, 2022 and 2031
Figure 75. Middle East & Africa Vaccines Market Attractiveness Analysis, Valance, 2023-2031
Figure 76. Middle East & Africa Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 77. Middle East & Africa Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
Figure 78. Middle East & Africa Vaccines Market Value Share Analysis, by Indication 2022 and 2031
Figure 79. Middle East & Africa Vaccines Market Attractiveness Analysis, Indication, 2023-2031
Figure 80. Middle East & Africa Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 81. Middle East & Africa Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Vaccines Market
